SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site)

ProSci
Product Code: PSI-9091
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-9091-0.02mg0.02mg£150.00
Quantity:
PSI-9091-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunofluorescence (IF)
  • Western Blot (WB)
Storage:
SARS-CoV-2 (COVID-19) Spike antibody (cleavage site) can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 8
<strong>Figure 1 SARS-Cov-2 Spike 681P Antibodies Specifically Do Not Recognize Omicron Variant Spike S1 Protein in an ELISA </strong><br>
Coating Antigen: SARS-CoV-2 spike S1 proteins WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and omicron variant (B.1.1.529), 1 μg/mL, incubated at 4 ˚C overnight.
Detection Antibodies: SARS-CoV-2 Spike 681P antibody, 9091, 1 μg/mL,, incubated at RT for 1 hr.
Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubate at RT for 1 hr.
<strong>SARS-CoV-2 spike 681P antibody (9091) can detect spike S1 protein of all other variants, but not omicron variant. </strong>
2 / 8
<strong>Figure 2 Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Spike (cleavage site) in 293 Transfected Cells</strong><br>Immunofluorescent analysis of 4% paraformaldehyde-fixed Spike transfected 293cells labeling SARS-CoV-2 (COVID-19) Spike (cleavage site) with 9091 at 10 mg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
3 / 8
<strong>Figure 3 Overexpression Validation in Spike Transfected 293 Cells </strong><br>Loading: 10 μg per lane of 293 cell lysate.  Antibodies: SARS-CoV-2 (COVID-19) Spike (cleavage site), 9091 (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.  Lane 1: WT 293 cells and Lane 2: SARS-CoV-2 Spike overexpressed 293 cells
4 / 8
<strong>Figure 4 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein </strong><br>Loading: 50 ng per lane of SARS-CoV-2  (COVID-19) Spike S1 recombinant protein (97-087).  Antibodies: SARS-CoV-2 (COVID-19) Spike (cleavage site), 9091, 1h incubation at RT  in 5% NFDM/TBST.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 μg/mL and Lane 2: 2 μg/mL.
5 / 8
<strong>Figure 5 ELISA Validation with SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein</strong><br>Antibodies: SARS-CoV-2 (COVID-19) Spike antibody (cleavage site), 9091 (1 μg/mL).  A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike S1 recombinant protein (97-087) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike antibody (cleavage site) as the capture antibody.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000ng/mL.
6 / 8
<strong>Figure 6 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike Recombinant Protein </strong><br>Loading: 30 ng per lane of SARS-CoV-2  (COVID-19) Spike RBD+SD1+SD2 recombinant protein, 10-305.  Antibodies: SARS-CoV-2 (COVID-19) Spike (cleavage site), 9091, 1h incubation at RT  in 5% NFDM/TBST.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 μg/mL, Lane 2: 2 μg/mL and Lane 3: 4 μg/mL.
7 / 8
<strong>Figure 7 ELISA Validation with SARS-CoV-2 (COVID-19) Spike Recombinant Protein</strong><br>Antibodies: SARS-CoV-2 (COVID-19) Spike antibody (cleavage site), 9091. A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike RBD+SD1+SD2 recombinant protein, 10-305, as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike antibody (cleavage site) as the capture antibody.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000ng/mL.
8 / 8
<strong> Figure 8 ELISA Validation of SARS-CoV-2 Spike Antibody Pair</strong><br>
A sandwich ELISA was performed using the anti-SARS-COV-2 Spike S1  antibodies  9091 (10 μg/mL ) as the capture antibody. Biotin-labled anti-SARS-COV-2 Spike S1  antibodies 9083-biotin (1 μg/mL ) and streptavidin-HRP (0.1 μg/mL ) were used for detection. Detection range is from 0.8 ng to 200 ng (SARS-CoV-2 Spike S1 Protein, 97-087).

<strong>Figure 1 SARS-Cov-2 Spike 681P Antibodies Specifically Do Not Recognize Omicron Variant Spike S1 Protein in an ELISA </strong><br>
Coating Antigen: SARS-CoV-2 spike S1 proteins WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and omicron variant (B.1.1.529), 1 μg/mL, incubated at 4 ˚C overnight.
Detection Antibodies: SARS-CoV-2 Spike 681P antibody, 9091, 1 μg/mL,, incubated at RT for 1 hr.
Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubate at RT for 1 hr.
<strong>SARS-CoV-2 spike 681P antibody (9091) can detect spike S1 protein of all other variants, but not omicron variant. </strong>
<strong>Figure 2 Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Spike (cleavage site) in 293 Transfected Cells</strong><br>Immunofluorescent analysis of 4% paraformaldehyde-fixed Spike transfected 293cells labeling SARS-CoV-2 (COVID-19) Spike (cleavage site) with 9091 at 10 mg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
<strong>Figure 3 Overexpression Validation in Spike Transfected 293 Cells </strong><br>Loading: 10 μg per lane of 293 cell lysate.  Antibodies: SARS-CoV-2 (COVID-19) Spike (cleavage site), 9091 (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.  Lane 1: WT 293 cells and Lane 2: SARS-CoV-2 Spike overexpressed 293 cells
<strong>Figure 4 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein </strong><br>Loading: 50 ng per lane of SARS-CoV-2  (COVID-19) Spike S1 recombinant protein (97-087).  Antibodies: SARS-CoV-2 (COVID-19) Spike (cleavage site), 9091, 1h incubation at RT  in 5% NFDM/TBST.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 μg/mL and Lane 2: 2 μg/mL.
<strong>Figure 5 ELISA Validation with SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein</strong><br>Antibodies: SARS-CoV-2 (COVID-19) Spike antibody (cleavage site), 9091 (1 μg/mL).  A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike S1 recombinant protein (97-087) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike antibody (cleavage site) as the capture antibody.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000ng/mL.
<strong>Figure 6 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike Recombinant Protein </strong><br>Loading: 30 ng per lane of SARS-CoV-2  (COVID-19) Spike RBD+SD1+SD2 recombinant protein, 10-305.  Antibodies: SARS-CoV-2 (COVID-19) Spike (cleavage site), 9091, 1h incubation at RT  in 5% NFDM/TBST.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 μg/mL, Lane 2: 2 μg/mL and Lane 3: 4 μg/mL.
<strong>Figure 7 ELISA Validation with SARS-CoV-2 (COVID-19) Spike Recombinant Protein</strong><br>Antibodies: SARS-CoV-2 (COVID-19) Spike antibody (cleavage site), 9091. A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike RBD+SD1+SD2 recombinant protein, 10-305, as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike antibody (cleavage site) as the capture antibody.  Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000ng/mL.
<strong> Figure 8 ELISA Validation of SARS-CoV-2 Spike Antibody Pair</strong><br>
A sandwich ELISA was performed using the anti-SARS-COV-2 Spike S1  antibodies  9091 (10 μg/mL ) as the capture antibody. Biotin-labled anti-SARS-COV-2 Spike S1  antibodies 9083-biotin (1 μg/mL ) and streptavidin-HRP (0.1 μg/mL ) were used for detection. Detection range is from 0.8 ng to 200 ng (SARS-CoV-2 Spike S1 Protein, 97-087).

Further Information

Additional Names:
SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site): Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein
Application Note:
WB: 0.5-4 μg/mL; IF: 20 μg/mL.

Antibody validated: Western Blot in human samples; Immunofluorescence in human samples. SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site) can be used for the detection of SARS-CoV-2 (COVID-19) Spike protein in ELISA. It will detect 4 ng of free peptide at 1 μg/mL. Antibody can also be used for as capture antibody in Sandwich Elisa at 10 μg/mL. All other applications and species not yet tested.
Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019?20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).
Background References:
  • Gorbalenya. bioRxiv: 2020.
  • Hui et al. Int J Infect Dis. 2020;91:264-266.
  • Belouzard et al. Viruses. 2012;4(6):1011-33.
  • Lee et al. J Virol. 2006;80(8):4079-87.
  • Wan et al. J Virol. 2020.
  • Wrapp et al. Science. 2020.
Buffer:
SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site) is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (25%)
Immunogen:
Anti-SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site) (9091) was raised against a peptide corresponding to 12 amino acids near the center of SARS-CoV-2 (COVID-19) Spike glycoprotein.

The immunogen is located within 650-700 amino acids of SARS-CoV-2 (COVID-19) Spike protein.
ISOFORMS:
SARS-CoV-2 (COVID-19) Spike has one isoform (1273aa).
NCBI Gene ID #:
43740568
NCBI Official Name:
surface glycoprotein
NCBI Official Symbol:
S
NCBI Organism:
SARS-CoV-2
Physical State:
Liquid
Protein Accession #:
QHD43416
Protein GI Number:
1791269090
Purification:
SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site) is affinity chromatography purified via peptide column.
Research Area:
Infectious Disease,COVID-19
Swissprot #:
P0DTC2
User NOte:
Optimal dilutions for each application to be determined by the researcher.